News

Link Technologies has reported the commercialisation and launch of a range of unlocked-nucleic acid (UNA) monomers under license from RiboTask. Under the terms of the agreement Link is

Arch Chemicals has reported sales of $350.5m for the third quarter of 2009, compared to $367.9m for the same period of 2008. Higher pricing and the benefit from

As part of a strategic initiative to expand the group’s limited presence in China, Novartis has entered into an agreement to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical

Peregrine Pharmaceuticals has received US Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies. It also includes Peregrine’s lead clinical compound, bavituximab. PS

Pfizer has exercised its option to license Flamel Technologies’ (Flamel) Medusa technology for the development of a controlled release formulation of an already-marketed therapeutic protein. Flamel is expected

Emerson Resources has formed a strategic partnership with Bio Research, to further extend its business development capabilities. The partnership leverages the expertise of industry veteran Robert Westbrook, CEO

PharmaForm, a wholly owned subsidiary of Akela Pharma has enhanced its portfolio of bioavailability enhancement solutions by adding aqueous and solvent spray drying. PharmaForm claimed that its processing

Antigenics has indicated that GlaxoSmithKline’s (GSK) Phase III malaria vaccine clinical trial, containing Antigenics’ QS-21 Stimulon adjuvant, has enrolled more than 5,000 children to date and is expected

Unilife Medical Solutions (Unilife Australia) has entered into a merger implementation agreement with Unilife Corporation (Unilife USA) to facilitate the proposed redomiciliation of the Unilife group in the